2026-10-12T06:55:53Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33954583 2026-10-01T14:54:38Z category_67901 portal_1154 item_type_5 month_year_10_2026

Congress presentation: IMS 2026 Prescription of Cytochrome P450 3A4 (CYP3A4) Modulators in Women Experiencing Natural Menopause Potentially Eligible for Treatment with Elinzanetant: A Large-Scale Real-World Study Cecile Janssenswillen (20937143) Katrin Manlik (22819837) Marcus-Hillert Schultze-Mosgau (21671090) Claudia Henn (20937149) Catherine Charbonneau (25137664) Nils Schoof (190380) Carina Dinkel-Keuthage (21812317) Menopause PRISM CYP3A4 Modulators IMS 2026 <p dir="ltr">Chronic use of CYP3A4 modulators was uncommon, suggesting that relatively few women potentially eligible for elinzanetant treatment would be impacted by label-related drug–drug interaction restrictions.</p> 2026-10-01T14:54:38Z Image Poster 10.71943/bayer.figshare.33954583.v1 https://figshare.com/articles/poster/Congress_presentation_IMS_2026_Prescription_of_Cytochrome_P450_3A4_CYP3A4_Modulators_in_Women_Experiencing_Natural_Menopause_Potentially_Eligible_for_Treatment_with_Elinzanetant_A_Large-Scale_Real-World_Study/33954583 CC BY-ND